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Abstract
Intellectual disability (ID) is a heterogeneous disorder caused by chromosomal abnormalities, monogenic factors and
environmental factors. 22q13 deletion syndrome is a genetic disorder characterized by severe ID. Although the frequency of
22q13 deletions in ID is unclear, it is believed to be largely underestimated. To address this issue, we used Affymetrix
Human SNP 6.0 array to detect the 22q13 deletions in 234 Chinese unexplained ID patients and 103 controls. After the
Quality Control (QC) test of raw data, 22q13 deletions were found in four out of 230 cases (1.7%), while absent in parents of
the cases and 101 controls. A review of genome-wide microarray studies in ID was performed and the frequency of 22q13
deletions from the literatures was 0.24%, much lower than our report. The overlapping region shared by all 4 cases
encompasses the gene SHANK3. A heterozygous de novo nonsense mutation Y1015X of SHANK3 was identified in one ID
patient. Cortical neurons were prepared from embryonic mice and were transfected with a control plasmid, shank3 wild-
type (WT) or mutant plasmids. Overexpression of the Y1015 mutant in neurons significantly affected neurite outgrowth
compared with shank3 WT. These findings suggest that 22q13 deletions may be a more frequent cause for Chinese ID
patients than previously thought, and the SHANK3 gene is involved in the neurite development.
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Introduction
Intellectual disability (ID), commonly referred to as develop-
mental delay (DD), mental retardation (MR) or learning disability,
is a developmental disorder characterized by significant impair-
ment of intellectual function and deficiency in two or more
adaptive behaviors, with onset before the age of 18 years.
Although the prevalence of ID varies with changes in diagnostic
criteria, assessment tools, medical services, culture, and social
custom, the estimates are between 1 and 3% in the general
population, making ID the most frequent cause of severe
handicaps in childhood and one of the main reasons for clinical
genetic referral and counseling. As an extremely heterogeneous
disorder, ID can be caused by a number of chromosomal
abnormalities, monogenic factors and environmental factors.
Down syndrome, Fragile X syndrome and fetal alcohol syndrome
are the most common syndromes associated with ID [1].
Chromosomal abnormalities, such as aneuploidies, rearrange-
ments, and subtelomeric deletions, play an important role in the
etiology of ID, accounting for nearly 40% of cases of moderate to
severe ID and approximately 10% of mild ID [2]. In a review of
16,673 patients, subtelomeric imbalances were reported in 586
cases (3.5%) [3]. New high-resolution microarray-based genomic
profiling technologies have enabled the detection of submicro-
scopic chromosomal imbalances (microdeletions/microduplica-
tions) throughout the genome. Consequently, genotype-phenotype
correlation studies have been undertaken to examine the clinical
significance of copy number variants (CNVs) in ID. Koolen et al.
reviewed 16 genome-wide microarray studies in 1,364 patients
with ID, 11.2% had detectable CNVs related to ID [4]. Sagoo et
al. [5] and Miller et al. [6] conducted similar systematic reviews
and found overall diagnostic yields of 10% and 12.2%,
respectively, for pathogenic genomic imbalances in individuals
with ID and/or congenital anomalies. Cooper et al. performed a
whole genome-wide array CGH study in 15,767 children with ID
and 8,329 unaffected adult controls and estimated that 14.2% of
ID was caused by CNVs.400 kb [7].
The 22q13 deletion syndrome, also known as Phelan-McDer-
mid Syndrome, is a microdeletion syndrome characterized by
severe ID, an absence of speech or a severely expressive speech
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dysmorphic features [8]. This syndrome results from the deletion
or disruption of the 22qter region. The frequency of the 22q13
deletion in ID is unclear, but it is believed to be largely
underestimated because of the lack of clinical recognition of this
syndrome and the limitations of routine cytogenetic techniques
used for experimental validation. Fluorescent in situ hybridization
(FISH), high-resolution chromosomal analysis and microarrays are
commonly used to detect this syndrome in the lab, and reported
deletion sizes range from 95 Kb to more than 9 Mb. In the
minimal critical region, the gene SHANK3 is a promising candidate
of causative genes for ID. SHANK3, predominantly expressed in
the cerebral cortex and cerebellum, encodes a scaffolding protein
found in excitatory synapses. It contains multiple protein-protein
interaction domains and functions as a master organizer of the
postsynaptic density (PSD). In an individual that represented the
main characteristics of 22q13 deletion syndrome, the SHANK3
gene was directly disrupted with a balanced translocation
t(12;22)(q24.1;q13.3) [9]. Anderlid et al. reported a 100 Kb
terminal 22q13 deletion which affected three genes including the
disruption of SHANK3 [10]. Durand et al. firstly sequenced all
SHANK3 exons in autism spectrum disorders (ASDs) and found a
frameshift mutation in one ASD individual [11]. Other indepen-
dent groups found more de novo missense mutations and gene
deletions of SHANK3 in ASD, supporting the involvement of
SHANK3 in the etiology of ASD [12,13]. Hamdan et al. sequenced
a large number of functional candidate genes for ID in 95 cases
and found a de novo splicing mutation of SHANK3 [14].
To address the frequency of 22q13 deletions in ID, we
performed a high-resolution microarray analysis in a cohort of
234 Chinese unexplained ID patients. Four out of 230 cases (1.7%)
were identified to have 22q13 deletions, of which the smallest
imbalance segment spanned 113 Kb. A heterozygous nonsense
mutation, Y1015X, was identified in a single case but was absent
in the unaffected parents and 556 controls. The overexpression of
SHANK3 Y1015X plasmid in primary cultured mouse cortical
neurons resulted in reduced numbers of neurite nodes and tips and
reduced cumulative length compared with neurons transfected
with wild-type (WT) SHANK3 plasmid.
Materials and Methods
Ethics Statement
The study was approved by the Ethics Committee of the Health
Science Center, Peking University and the Ethics Committee of
the School of Life Sciences, Fudan University. Informed, written
consent was obtained from the controls, the parents or guardians
of the children.
Subjects
A total of 234 Chinese patients (166 males and 68 females)
were recruited from the Department of Pediatrics, Peking
University First Hospital, China. The assessment methods and
inclusion criteria for the patients have been previously
described [15]. Briefly, patients with unexplained ID were
defined as those without evidence for any known genetic or
acquired disease causing ID after thorough clinical and related
lab evaluations. Gesell Developmental Schedules or Wechsler
intelligence scale for children was used to assess IQ scores. The
patients were excluded if they had the history of poisoning,
hypoxia, central nervous system infection, perinatal brain injury
and cranial trauma. Laboratory tests to rule out known genetic
causes of ID included standard karyotyping, metabolic screen-
ing, fragile X testing for male patients, and MECP2 gene
mutation analysis for female patients. All patients fulfilled the
DSM-IV criteria for ID. Ninety-five percent of the ID
individuals were Han Chinese.
Two cohorts of controls were recruited for this study. They were
103 Han Chinese controls (53 males and 50 females) for the whole
genome analysis of CNVs and 556 controls for the sequencing of
the SHANK3 gene.
Genomic DNA was extracted from whole blood according to
standard protocols.
Detection of CNVs
The Affymetrix Human SNP array 6.0 was used and it contains
more than 906,600 single nucleotide polymorphisms (SNPs) and
more than 946,000 probes for the detection of CNVs [16]. All 234
cases and 103 controls were genotyped using this array according
to the manufacturer’s protocol. Raw genotyping data were
acquired in the form of CEL files using the Affymetrix GeneChip
Command Console (AGCC) software.
CNVs were first analyzed using the Affymetrix Genotyping
Console 3.0.1 (GTC, Affymetrix) software. Those samples with
contrast Quality Control (QC) less than 0.4 were removed from
the subsequent CNV analysis. As a result, 230 patients and 101
controls passed the QC test and were included in the further
analyses. Average call rates for the cases and controls were 99.54%
and 98.28%, respectively. The copy number analysis was
performed using the BRLMM-P-Plus algorithm.
Additionally, the raw data were analyzed using three other
software packages including DNA-Chip Analyzer (dChip),
PennCNV and Birdsuite to validate the CNVs identified by
GTC and by each other. Those CNVs that were detected by at
least two of the four software packages were considered to be ‘true’
CNVs. Those CNVs characterized to have more than 50%
overlap by different software were considered to be the same
CNV.
MLPA confirmation of 22q13 deletion
Positive cases of 22q13 deletion were further confirmed using a
custom-designed MLPA assay. Additionally, the parents of these
patients were tested using the same MLPA to determine whether
the deletion was inherited or de novo. For MLPA analysis,
commercially available SALSAH MLPAH Reagents kits (MRC-
Holland, Amsterdam, Netherlands) were used. Probes specific for
SHANK3 were designed according to the recommended protocol
by MRC-Holland. The probe mix included SHANK3 exons 2, 3, 5,
9, 10, 12, 13, 16, 17, 20 and 22 as well as 4 PSPC1 probes included
for quality control. The MLPA reactions were performed
according to the manufacturer’s recommendation, using 250 ng
of DNA in a 5 ml reaction. Products were separated by capillary
electrophoresis on an ABI 3730 Genetic Analyzer (Applied
Biosystems, Foster City, CA), and the data were analyzed using
GeneMarker v1.85 (SoftGenetics LLC, State College, PA).
Threshold ratios for deletion and duplication were set at ,0.75
and .1.30, respectively.
Literature review of 22q13 deletion
A review of genome-wide microarray studies in patients with ID
was performed, from which the frequency of 22q13 deletion was
addressed. We used both free text and MeSH terms including
intellectual disability, mental retardation, developmental delay,
and microarray analysis to search the literature available in the
PubMed database of the National Center for Biotechnology
Information (NCBI) prior to Aug 2011. Included literature was
selected according to the following criteria. First, the description of
the study population was clear, and the majority of cases in each
22q13 Deletions and SHANK3 Mutations in ID
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experimental testing had various indications including ID,
dysmorphic features (DF), or multiple congenital anomalies
(MCA), the percentage of each subgroup should be mentioned
in the study to gauge whether the majority of the cases were
affected with ID. Second, the pre-tested karyotyping results were
normal for the patients. Third, the applied microarray method was
whole genomic, not targeted, analysis. Finally, pathogenic CNVs
identified in each study should be listed in detail so that the
number and location of the 22q13 deletion/duplication can be
analyzed.
Sequencing SHANK3 gene
The reference sequence for SHANK3 was acquired from the
UCSC Genome Browser (NM_001080420). All exons and exon-
intron junctions were sequenced in each of the 234 ID cases using
an ABI 3730XL sequencer. We were unable to successfully
sequence Exon 12 due to its high GC content. The primer
sequences used for amplification are available upon request. Each
of the 556 matched controls was genotyped using the SNaPshot
method.
Plasmid construction and transfection
Full-length rat Shank3 cDNA (pcGlobin2-HA-rat-shank3) was
received as a gift from Dr. Drapeau Pierre. Mutagenesis was
performed using the KOD-Plus-Mutagenesis Kit (Toyobo)
according to the manufacturer’s protocols. The human Y1015X
and A921T mutations identified in our samples correspond to
residues Y999X and V905T of the rat shank3 protein,
respectively. The primers utilized for A921T mutagenesis were:
forward 59-GCCAGAAGTGGGCGATACACCCCGGCCTG-
39 and reverse 59-CAGGCCGGGGTGTATCGCCCACTTC-
TGGC-39. The primers utilized for Y1015X mutagenesis were:
forward 59-GGGCGGCCTTGACTAGAGCTCTGGAGAAGG
-39 and reverse 59-CCTTCTCCAGAGCTCTAGTCAAGG-
CCGCCC -39. The PCR products were digested with restric-
tion enzymes AseI and ClaI and sub-cloned into Ubi-TM vector
t h a th a db e e nd i g e s t e dw i t hC l a Ia n dX h o I .E a c hc l o n ew a s
fully sequenced to confirm that no additional mutations were
induced.
E15 primary mouse cortical neurons were cultured in 12-well
plates as previously described [17,18]. Neurons were co-
transfected with GFP and empty plasmid or shank3 WT,
Y1015X, or A921T plasmids using lipofectamine 2000 (Invitro-
gen) at 4 days in vitro (DIV). Cells were fixed in 4%
paraformaldehyde for 20 min at room temperature. An anti-
GFP rabbit IgG pool (Invitrogen) and a secondary anti-rabbit
IgG antibody were applied, and the cells were visualized by
Nikon fluorescence microscopy.
Quantitative measurements of neurite outgrowth
Transfected neurons were selected at random from three
independent transfections for each construct (20–25 cells per
construct). Image J software from the National Institutes of
Health (NIH) was used to convert 16-bit images to 8-bit gray-
scale images. Neuronal morphology was traced using the
Neurolucida v9.0 system (MicroBrightField, Williston, VT). The
number of neurite, neurite nodes (branch points), neurite tips
(terminals) and the cumulative lengths of traced neurons were
calculated using NeuroExplorer (MicroBrightField, Williston,
VT). Statistical analysis was performed using a one-way ANOVA
and a Post Hoc test in SPSS10.0. The significance level was set at
P,0.05.
Results
Patients with 22q13 deletions
Four unrelated individuals with ID were found to have deletions
of 22q13 ranging in size from 113 Kb to 4.4 Mb. All 4 cases
shared a refined 113 Kb deletion that encompassed the gene
SHANK3 (Figure 1). These CNVs were identified by all four CNV-
calling algorithms, and we designed a MLPA assay as an
independent method to verify that all 22q13 deletions were
heterozygous. Blood samples were obtained from both parents in
cases 1 and 3 and one parent each for cases 2 and 4 to perform a
parental study of the 22q13 deletions by MLPA. The results
revealed that none of the parents carried the 22q13 imbalance.
The basic features of each of the 4 cases are summarized in
Table 1.
Case 1 (8 years old) was the only child of non-consanguineous
parents. He was born at 40 weeks after an uncomplicated vaginal
delivery with a normal birth weight (3 kg). He had severe ID with
an IQ of 30. He could not walk until 2 years of age and could not
use words at the time he was recruited into the study at 8 years of
age. The patient made no eye contact and no response to calling
and presented impaired social communication, restricted and
stereotyped patterns of behaviors and interests, and aggressive
behaviors. Physical examination identified a relatively small head
circumference. An MRI of the brain revealed no abnormalities.
His father exhibited mild stuttering, and his aunt had a mild
psychiatric abnormality that had not been clinically diagnosed.
Case 2 (6 years, and 9 months old) was the only child of non-
consanguineous parents. He had ID with an IQ,50. He showed
delayed motor development and prominent speech and language
developmental delays. At the age of 6 years and 9 months, he
could walk, speak simple words, and implement simple commands.
Additionally, he exhibited autistic behaviors such as poor eye
contact and restricted interests. Physical examination identified
one 966 mm cafe ´-au-lait spot on the skin. An MRI of the brain
revealed long T1 and T2 signals at the posterior horn of the
bilateral ventricles and the periventricle. Case 3 (2 years old) was
the only child of non-consanguineous parents. He was affected
with a severe developmental delay and hypotonia with an IQ,50.
When he was referred at the age of 2 years, he could not walk or
use words. There were no notable events in his family history.
Case 4 (13 years old) was the only child of non-consanguineous
parents. He exhibited delayed speech and motor development
with an IQ,50. He could not walk or speak simple words until the
age of 3 years. Physical examination revealed no abnormalities.
In summary, all cases presented with moderate to severe ID,
pronounced delays in speech and language development, and
abnormal motor development.
Low frequency of 22q13 deletion in the literature
In all, 21,281 cases from 29 studies were included for our
analysis of the literature (Table S1). Of 21,281 cases, the majority
was from Europe, America and Australia. Fifty-two cases with ID,
DF or MCA (0.24%) were identified to have the 22q13 deletion.
Compared with this result, the proportion of 22q13 deletions
involving SHANK3 in our Chinese cohort (1.7%, 4/230) was much
higher.
Mutation detection of SHANK3 and in vitro functional
analysis
We screened the coding region and exon-intron splice junctions
of the SHANK3 gene in 234 unrelated ID patients. An unreported
heterozygous nonsense mutation (Y1015X) was identified in one
case, and absent in the parents and 556 controls (Figure 2). The
22q13 Deletions and SHANK3 Mutations in ID
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34739Figure 1. High-density SNP-array Analysis of Chromosome 22q13 Deletions in Four Patients with ID. Microdeletions and duplications
are represented by red and blue bars respectively. Annotated genes in the overlapping region are shown in the bottom of the figure.
doi:10.1371/journal.pone.0034739.g001
Table 1. Basic features of 4 cases with 22q13 deletion.
Characteristics Case 1 Case 2 Case 3 Case 4
S e x MMMM
Age 8Y 6Y9M 2Y 13Y
CNV
Cytogenetic position 22q13.31-33 22q13.31-33 22q13.33 22q13.33
Physicial position 45193851–49581309 45908122–49581309 48993966–49581309 49468229–49581309
Del/dup del del del del
Size(Kb) 4387 3673 587 113
De novo/inherited de novo N
a de novo N
a
Affected genes 47 44 27 4
Developmental
Mental retardation ++++
Speech and language delay ++++
Motor development delay ++++
Autistic behaviour ++22
Physical
Dysmorphisms 2222
Hypotonia 22+ 2
MRI 2 + NN
Family history + 222
aN:just one parent of the case was tested with MLPA and did not carry the 22q13 deletion.
doi:10.1371/journal.pone.0034739.t001
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gene lead to a predicted truncated protein of 1,015 amino acid
residues compared with WT SHANK3 (1,747 amino acid).
Additionally, in another single case, we identified a missense
mutation (A921T) that was inherited from the patient’s mother
and absent in 556 controls. The boy was diagnosed with ID only.
The affected boy showed motor and intelligence developmental
delays. He could walk at the age of 26 months and speak simple
words at the age of three and half years. There was no positive
history of birth and family. Physical examination and MRI were
negative.
To determine whether SHANK3 mutations affect neuronal
morphology, we transfected primary mouse cortical neurons with
an empty vector or a vector encoding WT, A921T or Y1015X and
traced the neurons. Post Hoc tests showed that neurons transfected
with Y1015X had significantly decreased numbers of neurite
nodes and tips and decreased cumulative length compared with
neurons transfected with control, WT, or A921T (P,0.001,
Figure 2), while no significant difference in neurite number was
observed. No statistically phenotypic differences were observed
between A921T and WT. These results suggest that the SHANK3
Y1015X mutation plays an important role in neurite development,
while the A921T mutation is unlikely the causal mutation.
Discussion
Since the first case of 22q13 deletion syndrome was reported by
Watt in 1985 [19], the case reports have accumulated rapidly
[20,21]. However, the diagnosis of this disorder remains difficult in
the clinic because the features are non-specific and the
experimental testing is largely dependent on the resolution of the
methods available. More than ten different methods are used to
test for subtelomeric imbalances, with a variable resolution from
several Mb to 100 Kb or less. The known smallest deletion of
95 Kb was identified using the Agilent array-CGH 244K method
by Dhar et al. [22]. In the present study, the high-resolution
platform of the Affymetrix Human SNP 6.0 array was used to test
for CNVs in the Chinese population. Four out of 230 cases (1.7%)
were identified to carry deletions in 22q13 ranging in size from
113 Kb to 4.4 Mb.
We reviewed 29 genome-wide microarray studies of ID, DF or
MCA and identified 52 of 21,281 cases (0.24%) with 22q13
deletions. Compared with this data, the frequency of 1.7% for
22q13 deletion syndrome in our ID cohort is significantly higher,
supporting the widely held speculation that the frequency of 22q13
deletion has be underestimated. The possibility of false positive
cases was excluded since four different software packages were
used to detect the CNVs and the positive cases were validated by
MLPA. The discrepancy of the frequency could be explained by
the complexity of sample phenotypes, heterogeneity of genetic
factors and various experimental methods. During the literature
review, we included the studies based on the criteria that the
majority of the cases in each report were affected with ID, but the
situation of co-morbidity and the ascertainment methods were
various among different studies. The phenotypic complexity of the
samples could result from the heterogeneity of genetic factors.
BAC arrays or low-resolution microarrays were used to detect
CNVs in most studies reviewed. In this study, we screened all
segments longer than 50 Kb for CNVs using Affymetrix Human
SNP 6.0 array. Compared to conventional karyotyping and low-
resolution microarrays, the high-resolution microarray methods
such as SNP 6.0 could cut down the false negative rates.
Affymetrix Human SNP 6.0 array could detect smaller
CNVs,500 Kb, even,100 Kb. The 29 genome-wide microarray
ID studies reviewed in the literature were performed in primarily
Caucasian populations, while the subjects in this study were
exclusively Chinese. Jiang et al. screened 451 Chinese ID cases for
CNV detection using subtelomere-MLPA method. Two deletions
and one duplication in 22q13 were identified, accounting for
0.67% of cases.[15] We used the same ethnic population screened
by the same including and excluding criteria, but compared with
Jiang’s study, we used different methods to access the frequency of
22q13 CNVs in ID. The Affymetrix Human SNP 6.0 array we
used has detailed probes with an average spatial resolution of
700 bp, while subtelomere-MLPA contains only a few probes for a
certain region of chromosomes, which is expected to have low
detection rate. Our results suggest that the frequency of 22q13
deletions is unexpected high in Chinese ID patients. A limitation
of this study was the relatively small sample size (230 cases versus
101 controls). For this reason, more samples from Chinese
population should be studied to validate these preliminary results.
It should be mentioned that we found one female DD case
carrying a 22q13 duplication of 5.86 Mb, spanning 22q13.31 to
22qter. However, a detailed clinical phenotype was not available
as this subject died at the age of 2 years and therefore was not
included in our analysis.
The smallest CNV in 22q13 that we identified spanned 113 Kb
and affected the gene SHANK3. One de novo nonsense mutation
(Y1015X) in SHANK3 was identified in ID. The mutation of
tyrosine substituted by a stop codon at amino acid position 1015
(Y1015X) leads to a predicted truncated protein lacking the
Homer- and Cortactin-binding sites as well as the sterile a motif
(SAM) domain. The mouse cortical neurons transfected with
Y1015X construct showed dramatically decreased numbers of
neurite tips and nodes and the cumulative length compared with
control, WT and A921T. We also identified a missense mutation
A921T in an ID patient, inherited from his unaffected mother.
Functional analysis did not find any influence of this mutation on
neurite development. Both the inheritable transmission pattern
and non-functional effect indicated that mutation A921T might be
benign.
Our results showed that SHANK3 protein is important for
neurogenesis, consistent with other reports [23,24,25,26]. Effects
of SHANK3 on dendritic spine synapses in neurons were
demonstrated by the fact that the knock-down of Shank3 by
RNA interference in hippocampal neurons reduces spine density,
whereas transfection of this protein in aspiny neurons induces
formation of new functional synapses [23]. The study of Shank3
heterozygous mice also found that haploinsufficiency of Shank3
resulted in a decrease in synaptic transmission, altered functional
and structural plasticity of synapses and reduced social behaviors
[24]. Meanwhile, mice with homozygous Shank3 gene deletions
displayed morphological defects of spiny neurons, including
neuronal hypertrophy and a significant reduction in spine density
[25]. Shank3 was further found to be at the tip of actin filaments
and participates in growth cone motility in developing neurons.
SHANK3 mutations identified in autism affect the development
and morphology of dendritic spines via an actin-dependent
mechanism [26].
SHANK3 is a binding partner of neuroligin, which is expressed
in postsynaptic neurons and interacts with presynaptic neurexins.
Neuroligins-Neurexins pathways are believed to play an important
role in the pathogenesis of neurodevelopmental disorders.
Mutations in SHANK3 have been reported in individuals with
mental retardation, autism, and pervasive developmental delays
[27]. Interestingly, Gauthier et al. sequenced the SHANK3 gene in
185 schizophrenia patients and detected a de novo nonsense
R1117X mutation in one patient and his two affected brothers
22q13 Deletions and SHANK3 Mutations in ID
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34739Figure 2. Identification and functional analysis of SHANK3 mutations. (A) Pedigree of the proband with a de novo Y1015X mutation and
localization of this nonsense variation on the linear protein structure of SHANK3. ANK, ankyrin repeats; SH3, Src homology 3 domain; PDZ,
postsynaptic density protein; SAM, sterile a motif domain. (B) Representative photographs demonstrating the anatomic differences in traced neurons
transfected with empty vector, SHANK3 WT, A921T, or Y1015X vectors, respectively. (C–F) Analysis of SHANK3 mutations in primary mouse cortical
neuronal cultures. Neurite number (C), nodes (D), tips (E) and total length (F) are quantified in bar histograms along with standard error of the mean
for each bar. Asterisks indicate a statistically significant difference (**P,0.001, Post Hoc tests). Compared to control, WT and A921T, the
overexpression of Y1015X significantly decreased neurite complexity and length.
doi:10.1371/journal.pone.0034739.g002
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for neurodevelopmental disorders, there was only one report about
the mutation screening of this gene in ID [14]. Our report was the
second one about the mutation screening of SHANK3 gene in ID
and sample size was larger than the first one (95 individuals).
These evidences suggest that phenotypic variations as a result of
SHANK3 mutations are quite broad and that ID, ASDs and
schizophrenia may share common etiological factors.
In conclusion, this study indicates that frequency of 22q13
deletion is as high as 1.7% in Chinese ID population. The
observation of frequent 22q13 deletions and a mutation that led to
impaired function of SHANK3 in ID patients supports the
haploinsufficiency role in etiology of ID.
Supporting Information
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